We are live on ! Find out more
MG

Michael Gelband ExodusPoint Capital Management

AUM $15.5B
1-Year Est. Return 38.81%
 

Michael Gelband is a co-founder of ExodusPoint Capital Management, a multi-strategy hedge fund launched by veterans of larger alternative platforms. The firm pursues diversified strategies across asset classes with a focus on risk-managed absolute returns. Gelband’s firm is followed as part of the newer generation of multi-strategy complexes.

This Fund
S&P 500
This Quarter Est. Return
+7.87%
1 Year Est. Return
+38.81%
3 Year Est. Return
+110.53%
5 Year Est. Return
+124.16%
10 Year Est. Return
AUM
$9.04B
AUM Growth
+$2.19B
Cap. Flow
+$1.88B
Cap. Flow %
20.78%
Top 10 Hldgs %
34.88%
Holding
3,092
New
1,032
Increased
581
Reduced
587
Closed
820

Top Buys

Rank Stock Value
1
MSFT icon
Microsoft
MSFT
+$435M
2
AMZN icon
Amazon
AMZN
+$334M
3
MRNA icon
Moderna
MRNA
+$53.9M
4
LIN icon
Linde
LIN
+$44.2M
5
DTE icon
DTE Energy
DTE
+$43.5M

Sector Composition

Rank Sector Weight
1 Technology 15.37%
2 Consumer Discretionary 10.36%
3 Financials 7.14%
4 Industrials 6.8%
5 Healthcare 6.46%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
REV
2001
DELISTED
Revlon, Inc.
REV
$192K ﹤0.01%
+14,955
New +$188K
ENZL icon
2002
iShares MSCI New Zealand ETF
ENZL
$85.8M
$191K ﹤0.01%
+3,147
New +$198K
SMFG icon
2003
Sumitomo Mitsui Financial
SMFG
$160B
$191K ﹤0.01%
27,710
-55,932
-67% -$401K
VRN
2004
DELISTED
Veren
VRN
$191K ﹤0.01%
42,145
-28,200
-40% -$118K
LUNA
2005
DELISTED
Luna Innovations Incorporated
LUNA
$189K ﹤0.01%
+17,469
New +$190K
TIPT icon
2006
Tiptree Inc
TIPT
$685M
$188K ﹤0.01%
+20,245
New +$214K
INFN
2007
DELISTED
Infinera Corporation Common Stock
INFN
$188K ﹤0.01%
18,457
-14,175
-43% -$137K
WCLD
2008
WisdomTree Cloud Computing Fund
WCLD
$330M
$186K ﹤0.01%
+3,320
New +$168K
INTZ
2009
DELISTED
INTRUSION INC NEW
INTZ
$186K ﹤0.01%
12,100
-20,397
-63% -$314K
SPHD icon
2010
Invesco S&P 500 High Dividend Low Volatility ETF
SPHD
$3.45B
$185K ﹤0.01%
+4,205
New +$188K
TCRR
2011
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
$185K ﹤0.01%
+11,286
New +$228K
LDI icon
2012
loanDepot
LDI
$312M
$184K ﹤0.01%
+14,300
New +$233K
ASPU
2013
DELISTED
ASPEN GROUP, INC.
ASPU
$184K ﹤0.01%
+28,289
New +$161K
TPC
2014
Tutor Perini Cor
TPC
$4.59B
$183K ﹤0.01%
+13,187
New +$210K
QUAD icon
2015
PUT
Quad
QUAD
$526M
$182K ﹤0.01%
+44,100
New +$160K
STKS icon
2016
The ONE Group
STKS
$52.4M
$182K ﹤0.01%
16,560
-28,459
-63% -$289K
TCRT icon
2017
Alaunos Therapeutics
TCRT
$4.55M
$182K ﹤0.01%
+459
New +$214K
PVG
2018
DELISTED
PRETIUM RESOURCES INC.
PVG
$182K ﹤0.01%
19,081
-61,595
-76% -$673K
TECX
2019
Tectonic Therapeutic
TECX
$737M
$181K ﹤0.01%
+1,693
New +$201K
BSBR icon
2020
Santander
BSBR
$43.4B
$180K ﹤0.01%
+22,875
New +$170K
RC
2021
Ready Capital
RC
$329M
$180K ﹤0.01%
+11,361
New +$168K
TDAY
2022
USA Today Co
TDAY
$953M
$179K ﹤0.01%
32,676
-18,060
-36% -$92.2K
JNCE
2023
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$177K ﹤0.01%
26,064
+15,189
+140% +$126K
UBX
2024
DELISTED
Unity Biotechnology
UBX
$176K ﹤0.01%
3,789
+1,457
+62% +$70.2K
CCO icon
2025
Clear Channel Outdoor Holdings
CCO
$1.21B
$175K ﹤0.01%
66,180
-1,920,363
-97% -$4.6M

Similar funds

Michael Gelband's Q2 2021 Portfolio in Review

As of Q2 2021, Michael Gelband held 3,092 positions worth $9.04B, up 32% from $6.86B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Michael Gelband deployed $1.88B of net new capital in Q2 2021, opening 1,032 new positions and adding to 581 existing holdings. Its largest new stake was Linde: 151,692 shares worth $43.9M.

By sector, the portfolio is most concentrated in Technology at 15% of assets, up from 13% a quarter earlier, followed by Consumer Discretionary and Financials.

On the sell side, the largest reduction was iShares Russell 1000 Value ETF, an estimated $63.6M trimmed.

  • Michael Gelband's largest Q2 2021 buy was Linde: 151,692 shares worth $43.9M.
  • Michael Gelband added most to Microsoft in Q2 2021, an estimated $435M increase.
  • Michael Gelband's biggest Q2 2021 reduction was iShares Russell 1000 Value ETF, cutting an estimated $63.6M.
  • Michael Gelband fully exited Charles River Laboratories in Q2 2021, selling an estimated $27.9M.
  • Michael Gelband's ten largest holdings make up 35% of its $9.04B portfolio in Q2 2021.
  • Michael Gelband opened 1,032 new positions and closed 820 in Q2 2021.
  • Michael Gelband's portfolio value rose 32% quarter-over-quarter to $9.04B.

Based on ExodusPoint Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.